Eris Lifesciences Ltd
NSE:ERIS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
831.3
1 468.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ERIS stock under the Base Case scenario is 1 082.77 INR. Compared to the current market price of 1 374.2 INR, Eris Lifesciences Ltd is Overvalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eris Lifesciences Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ERIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Eris Lifesciences Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eris Lifesciences Ltd
Balance Sheet Decomposition
Eris Lifesciences Ltd
Current Assets | 23B |
Cash & Short-Term Investments | 964.7m |
Receivables | 4.3B |
Other Current Assets | 17.8B |
Non-Current Assets | 47.5B |
Long-Term Investments | 248.7m |
PP&E | 5.2B |
Intangibles | 38.2B |
Other Non-Current Assets | 3.7B |
Current Liabilities | 25.3B |
Accounts Payable | 2.7B |
Other Current Liabilities | 22.6B |
Non-Current Liabilities | 19.3B |
Long-Term Debt | 6.9B |
Other Non-Current Liabilities | 12.4B |
Earnings Waterfall
Eris Lifesciences Ltd
Revenue
|
22.6B
INR
|
Cost of Revenue
|
-4.8B
INR
|
Gross Profit
|
17.8B
INR
|
Operating Expenses
|
-12.4B
INR
|
Operating Income
|
5.4B
INR
|
Other Expenses
|
-1.6B
INR
|
Net Income
|
3.8B
INR
|
Free Cash Flow Analysis
Eris Lifesciences Ltd
INR | |
Free Cash Flow | INR |
Eris Lifesciences reported a consolidated Q1 revenue of INR 720 crores, marking a 54% year-over-year increase, and an EBITDA of INR 250 crores, a 47% rise. The company successfully integrated Biocon acquisitions, achieving substantial synergies. The Biocon segment alone is expected to contribute 25% growth in FY '25. Eris' model now encompasses specialty and super specialty segments, including oncology and critical care. The guidance for the year includes a revenue target of over INR 3,000 crores and an EBITDA margin of 35%.
What is Earnings Call?
ERIS Profitability Score
Profitability Due Diligence
Eris Lifesciences Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Eris Lifesciences Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
ERIS Solvency Score
Solvency Due Diligence
Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERIS Price Targets Summary
Eris Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for ERIS is 1 543.77 INR with a low forecast of 1 242.3 INR and a high forecast of 1 764 INR.
Dividends
Current shareholder yield for ERIS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ERIS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one ERIS stock under the Base Case scenario is 1 082.77 INR.
Compared to the current market price of 1 374.2 INR, Eris Lifesciences Ltd is Overvalued by 21%.